What patent covers givenostat, and who holds it?
The provided information does not specify which “givinostat” patent you mean (for example, brand/company assignees, jurisdiction, or patent number). Without a patent identifier or additional context (company name, filing country, or a specific patent number/publication), it’s not possible to accurately state what it covers or who owns it.
When does the givenostat patent expire?
Patent expiration depends on the exact patent (publication number), the country (for example, US, EP, JP), and whether any extensions apply (such as term adjustments or supplementary protection certificates). The provided information does not include those details, so a precise expiration date cannot be given.
Are there multiple givenostat patents (compound, formulation, or method-of-use)?
Drug portfolios commonly include several patent families (covering the active compound, compositions/formulations, and specific uses). Determining how many and which ones apply to givenostat requires the patent numbers or at least the assignee and jurisdiction.
Could generic or biosimilar competitors enter before patent expiry?
Whether market entry is possible early depends on the specific patent landscape (which patents are still in force, and whether any are challenged or design-around). No patent status or litigation details were provided, so this can’t be answered for givenostat as-is.
How can you identify the right “givenostat patent” quickly?
If you share any one of the following, the patent details can be narrowed to the exact documents you need:
- The patent number or publication number (USxxxxxxx, EPxxxxxxx, WOxxxxxxx, etc.)
- The company/assignee name tied to givenostat
- The country or region you care about (US, Europe, UK, etc.)
- Where you saw the phrase “Givinostat patent” (link, screenshot text, or article title)
What I need from you to give a specific answer
Reply with the patent number/publication (or the assignee + jurisdiction). Then I can tell you:
- what the patent claims (compound vs method vs formulation),
- when it expires (and whether extensions exist),
- and whether other patents in the same family might still block entry.
Sources
No sources were provided in the prompt.